Abstracts Archive - Page 1645 of 2607 - ACR Meeting Abstracts

Abstract Number: 683 • 2016 ACR/ARHP Annual Meeting
Risk Factors of Uveitis in Ankylosing Spondylitis
Feng Wang¹, Qin Xue², Li Sun³ and Niansong Wang⁴, ¹Nephrology and Rheumatology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China, ²Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China, ³Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing, China, ⁴Shanghai Jiao Tong University Affiliated Sixth People's Hospital, shanghai, China
Background/Purpose: Uveitis is the most common extra-articular manifestation in patients with ankylosing spondylitis (AS).The prevalence and characteristics of uveitis in AS have been studied in previous literatures while…
Abstract Number: 684 • 2016 ACR/ARHP Annual Meeting
Subchondral Bone Sclerosis on Computed Tomography – Does It Have Any Value in the Diagnosis of Inflammatory Sacroiliitis or Is It a Non-Specific Finding?
Omar Azmat¹, Robert G. Lambert², Zaid Jibri³ and Walter Maksymowych⁴, ¹Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada, ²Radiology, University of Alberta, Edmonton, AB, Canada, ³Diagnostic Imaging, The Ottawa Hospital, Ottawa, ON, Canada, ⁴Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Sclerosis in the sacroiliac joints (SIJ) on radiography and computed tomography (CT) is common but widely considered a non-specific finding…
Abstract Number: 685 • 2016 ACR/ARHP Annual Meeting
Paradoxical Psoriasis Secondary to Anti-Tnfa Agents in Patients with Ankylosing Spondylitis: A Nationwide Population-Based Cohort Study
Ki-Jo Kim¹, Jung Min Bae², Young Bin Joo³, In-Woon Baek⁴, Kyung-Su Park³ and Chul-Soo Cho⁴, ¹Internal Medicine, St. Vincent’s Hospital, The Catholic University of Korea, Suwon, Korea, The Republic of, ²Dermatology, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea, The Republic of, ³Internal Medicine, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea, The Republic of, ⁴Internal Medicine, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Anti-tumor necrosis factor-alpha (anti-TNFa) agents are established as the mainstay of treatment for ankylosing spondylitis (AS). Recently, paradoxical induction or exacerbation of psoriatic skin…
Abstract Number: 686 • 2016 ACR/ARHP Annual Meeting
Development and Evaluation of the Combined Ankylosing Spondylitis Spine Score (CASSS) for the Assessment of Spinal Radiographic Outcome
Fiona Maas¹, Anneke Spoorenberg^1,2, Elisabeth Brouwer¹, Hendrika Bootsma³, Reinhard Bos², Freke Wink² and Suzanne Arends^1,2, ¹Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology, Medical Center Leeuwarden, Leeuwarden, Netherlands, ³Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, The Netherlands, Groningen, Netherlands
Background/Purpose: Spinal radiographic progression is a highly variable process in ankylosing spondylitis (AS). Our aim was to develop a combined AS spine score (CASSS) in…
Abstract Number: 687 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of Certolizumab Pegol over 204 Weeks in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Atul A. Deodhar¹, Maxime Dougados², Robert Landewé³, Joachim Sieper⁴, Walter Maksymowych⁵, Martin Rudwaleit⁶, Filip van Den Bosch⁷, Jürgen Braun⁸, Philip J Mease⁹, Alan Kivitz¹⁰, Jessica Walsh¹¹, Owen Davies¹², Bengt Hoepken¹³, Luke Peterson¹⁴ and Désirée van der Heijde¹⁵, ¹Divison of Arthritis and Rheumatic Diseases, Oregon Health and Science University, Portland, OR, ²Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ³Academic Medical Center, Amsterdam and Zuyderland Medical Center, Heerlen, Netherlands, ⁴Rheumatology Department, Charité – University Medicine Berlin, Berlin, Germany, ⁵Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁶Klinikum Bielefeld and Charité – University Medicine Berlin, Berlin, Germany, ⁷University Hospital Ghent, Ghent, Belgium, ⁸Rheumazentrum Ruhrgebiet, Herne, Germany, ⁹Swedish Medical Center and University of Washington, Seattle, WA, ¹⁰Altoona Center for Clinical Research, Duncansville, PA, ¹¹Division of Rheumatology, University of Utah School of Medicine, Salt Lake City, UT, ¹²UCB Pharma, Slough, United Kingdom, ¹³UCB Pharma, Monheim, Germany, ¹⁴UCB Pharma, Raleigh, NC, ¹⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: RAPID-axSpA (NCT01087762) investigated the efficacy and safety of certolizumab pegol (CZP) in patients (pts) with axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS) and non-radiographic…
Abstract Number: 688 • 2016 ACR/ARHP Annual Meeting
Spondyloarthritis Research Consortium of Canada (SPARCC) Baseline MRI SI Joint Score ≥2 Better Predicts Response to Golimumab Than Does Assessment of Spondyloarthritis International Society (ASAS) MRI Positivity in Nonradiographic Axial Spondyloarthritis
Walter Maksymowych¹, Anjela Tzontcheva², George Philip², Gina Bergman², Susan Huyck² and Sean P. Curtis², ¹Medicine, University of Alberta, Edmonton, AB, Canada, ²Merck & Co., Inc., Kenilworth, NJ
Background/Purpose: Golimumab (GLM) was shown to be effective for nonradiographic axial spondyloarthritis (nr-axSpA) in a randomized, double-blind, placebo-controlled, phase 3 study (GO-AHEAD; NCT01453725).1 The SPondyloArthritis…
Abstract Number: 689 • 2016 ACR/ARHP Annual Meeting
Relationship Between Infliximab Serum Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis
Theodora Bejan-Angoulvant¹, David Ternant², Fadela Daoued³, Frédéric Medina³, Louis Bernard⁴, Saloua Mammou³, Gilles Paintaud² and Denis Mulleman⁵, ¹Service de Pharmacologie Clinique, CHRU de Tours, Université François-Rabelais de Tours, CNRS 7292, CHRU de Tours, Tours, France, ²Laboratoire de Pharmacologie-Toxicologie, Université François-Rabelais de Tours, CNRS 7292, CHRU de Tours, Tours, France, ³Service de Rhumatologie, Université François-Rabelais de Tours, CHRU de Tours, Tours, France, ⁴Service des Maladies Infectieuses, Université François-Rabelais de Tours, CHRU de Tours, Tours, France, ⁵Service de Rhumatologie, Rheumatology department, François-Rabelais University, CNRS 7292, CHRU de Tours, Tours, France
Background/Purpose: Tumour necrosis factor alpha inhibitors are effective in reducing inflammation in rheumatic diseases while increasing the risk of infections. We aimed to study the…
Abstract Number: 690 • 2016 ACR/ARHP Annual Meeting
Increase in Serum Leptin Levels Is Associated with Radiographic Progression of Male Patients with Ankylosing Spondylitis: A 2-Year Longitudinal Study
Seung-Geun Lee¹, Eun-Kyoung Park², Ji-Heh Park¹, Hee-Sang Tag³ and Geun-Tae Kim⁴, ¹Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, Korea, The Republic of, ²Division of Rheumatology, Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, Kosin University College of Medicine, Busan, South Korea, ⁴Kosin University College of Medicine, Busan, South Korea
Background/Purpose: The immunomodulatory effects of adipokines have been extensively studied in rheumatic diseases, there is a paucity of information regarding their effects on bone metabolism.…
Abstract Number: 691 • 2016 ACR/ARHP Annual Meeting
ASAS Health Index for Patients with Spondyloarthritis: Translation into Spanish, Validation, Reliability and Construct Validity
Wilson Bautista-Molano^1,2, Robert Landewé³, Uta Kiltz⁴, Rafael Valle-Oñate⁵ and Désirée van der Heijde⁶, ¹Rheumatology, Leiden University Medical Center, Bogotá, Colombia, ²Rheumatology Department School of Medicine HMC / UMNG, Bogotá, Colombia, ³Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Rheumatology, Rheumatology Department School of Medicine HMC / UMNG, Bogota, Colombia, ⁶Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The aim of the study was to develop and validate a Spanish-language translation of the ASAS Heath Index (ASAS-HI) testing its reliability, construct validity…
Abstract Number: 692 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Biological Therapy and Target Synthetic Dmards: A Systematic Literature Review Informing the 2016 Update of the ASAS/EULAR Recommendations for the Management of Axial Spondyloarthritis
Alexandre Sepriano¹, Andrea Regel², Désirée van der Heijde¹, Jürgen Braun², Xenofon Baraliakos², Robert Landewé³, Filip van Den Bosch⁴ and Sofia Ramiro¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁴Rheumatology, Ghent University Hospital, Gent, Belgium
Background/Purpose: As part of the update of the ASAS/EULAR recommendations for the management of axSpA, we performed a systematic literature review to assess the efficacy…
Abstract Number: 693 • 2016 ACR/ARHP Annual Meeting
The Prevalence of Axial and Peripheral Spondyloarthritis in Inflammatory Bowel Disease: A Systematic Review & Meta-Analysis
Maren C. Karreman^1,2, Jolanda J. Luime³, Johanna M.W. Hazes² and Angelique E.A.M. Weel¹, ¹Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ²Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ³Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands
Background/Purpose: Inflammatory Bowel Disease (IBD) is a chronic disease that affects up to 0.5% of the population, comprising both Crohn’s Disease (CD) and ulcerative colitis…
Abstract Number: 694 • 2016 ACR/ARHP Annual Meeting
Diagnostic Delay Leads to Worse Response to Treatment
Marijn Vis¹, Kim Wervers², Ilja Tchetverikov³, Mark R. Kok⁴, Lindy-Anne Korswagen⁵, Andreas H. Gerards⁶, Hans van Groenendaal⁷, Jozien Veris⁸, Wiebo L. van der Graaff⁹, Cathelijne W. Y. Appels¹⁰, Johanna M.W. Hazes¹¹ and Jolanda J. Luime¹, ¹Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands, ²Erasmus Medical Centre, Rotterdam, Netherlands, ³Albert Schweitzer Hospital, Dordrecht, Netherlands, ⁴Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁵Sint Franciscus Gasthuis, Rotterdam, Netherlands, ⁶Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁷Rheumatology, ReumaZorg ZuidWest nederland, Roosendaal, Netherlands, ⁸Rheumatology, Reumazorg Zuid West Nederland, Goes, Netherlands, ⁹Rheumatology, Rivas hospital, Gorinchem, Netherlands, ¹⁰Rheumatology, Amphia Hospital, Breda, Netherlands, ¹¹Department of Rheumatology, Erasmus University Medical Centre, Rotterdam, Netherlands
Is there a clinical patient profile for PsA Patients with a diagnostic delay? Background/Purpose: Psoriatic arthritis (PsA) is a progressive inflammatory musculoskeletal disease. Several recent…
Abstract Number: 695 • 2016 ACR/ARHP Annual Meeting
Secukinumab Sustains Individual Clinical Responses over Time in Patients with Active Ankylosing Spondylitis: 2-Year Results from a Phase 3 Randomized Placebo-Controlled Trial
Xenofon Baraliakos¹, Michael Schiff², Karel Pavelka³, Ruvie Martin⁴, Brian Porter⁴ and Corine Gaillez⁵, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²University of Colorado, School of Medicine, Denver, CO, ³Institute and Cliníc of Rheumatology, Charles University, Prague, Czech Republic, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵Novartis Pharma AG, Basel, Switzerland
Background/Purpose: The assessment of achieving, maintaining, and improving clinical response to biologics in Ankylosing Spondylitis (AS) is part of treat-to-target recommendations aimed at optimizing treatment…
Abstract Number: 696 • 2016 ACR/ARHP Annual Meeting
Significantly Reduced Recurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis during Treatment with Golimumab
S.C. Heslinga^1,2, M. T. Nurmohamed^1,3, A. H. Gerards⁴, E. Griep⁵, C. Koehorst⁶, M. R. Kok⁷, A. Schilder⁸, M. Verhoef⁹ and I.E. Van der Horst - Bruinsma^1,2, ¹Rheumatology, Reade, Amsterdam Rheumatology and immunology Center, Reade, Amsterdam, Netherlands, ²Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands, ³Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands, ⁴Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁵Rheumatology, Antonius Hospital, Sneek, Netherlands, ⁶Rheumatology, Gelre Hospital, Apeldoorn, Netherlands, ⁷Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁸Rheumatology, Medical Centre Leeuwarden, Leeuwarden, Netherlands, ⁹Immunology, MSD the Netherlands, Haarlem, Netherlands
Background/Purpose: Acute anterior uveitis (AAU) is common in ankylosing spondylitis (AS) (1). Golimumab, a tumor necrosis factor alpha (TNF-α) blocker, has proven to be effective…
Abstract Number: 697 • 2016 ACR/ARHP Annual Meeting
Does Axial Spondyloarthritis Phenotype Correlate with Imaging Morphotype?
Xenofon Baraliakos¹, Annette Szumski², Heather Jones³ and Lianne S. Gensler⁴, ¹Rheumazentrum, Ruhr University, Bochum, Germany, ²inVentiv Health, Princeton, NJ, ³Inflammation & Immunology, Pfizer, Collegeville, PA, ⁴Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Traditionally, radiographic imaging was used to describe morphological differences between various types of axial SpA (axSpA). MRI has advanced understanding of disease, enabled earlier…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].